Research Analysts Offer Predictions for Adamas Pharmaceuticals Inc’s FY2019 Earnings (NASDAQ:ADMS)

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) – Research analysts at Piper Sandler raised their FY2019 EPS estimates for shares of Adamas Pharmaceuticals in a note issued to investors on Tuesday, February 11th. Piper Sandler analyst D. Amsellem now anticipates that the specialty pharmaceutical company will post earnings per share of ($3.85) for the year, up from their prior forecast of ($3.87). Piper Sandler also issued estimates for Adamas Pharmaceuticals’ Q4 2019 earnings at ($0.88) EPS, Q1 2020 earnings at ($0.77) EPS, Q3 2020 earnings at ($0.51) EPS, Q4 2020 earnings at ($0.47) EPS, FY2020 earnings at ($2.33) EPS, Q1 2021 earnings at ($0.53) EPS, Q2 2021 earnings at ($0.50) EPS, Q3 2021 earnings at ($0.51) EPS, Q4 2021 earnings at ($0.48) EPS, FY2021 earnings at ($1.79) EPS, FY2022 earnings at ($0.94) EPS and FY2023 earnings at $0.38 EPS.

ADMS has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective (down previously from $30.00) on shares of Adamas Pharmaceuticals in a research report on Wednesday, December 18th. Needham & Company LLC reiterated a “hold” rating on shares of Adamas Pharmaceuticals in a research report on Tuesday, December 17th. Northland Securities reiterated a “buy” rating and set a $15.00 price objective on shares of Adamas Pharmaceuticals in a research report on Friday, November 8th. Evercore ISI reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Monday, December 9th. Finally, ValuEngine upgraded Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. Adamas Pharmaceuticals currently has an average rating of “Hold” and an average price target of $14.63.

Shares of Adamas Pharmaceuticals stock opened at $5.61 on Friday. Adamas Pharmaceuticals has a one year low of $3.35 and a one year high of $12.57. The company has a market cap of $158.08 million, a price-to-earnings ratio of -1.39 and a beta of 1.66. The company has a debt-to-equity ratio of 6.72, a quick ratio of 6.15 and a current ratio of 6.35. The business’s 50 day moving average price is $5.15 and its 200 day moving average price is $5.39.

Large investors have recently bought and sold shares of the business. Parametric Portfolio Associates LLC bought a new stake in shares of Adamas Pharmaceuticals during the second quarter valued at approximately $173,000. BlackRock Inc. raised its holdings in shares of Adamas Pharmaceuticals by 5.4% during the second quarter. BlackRock Inc. now owns 2,195,088 shares of the specialty pharmaceutical company’s stock valued at $13,609,000 after buying an additional 112,278 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Adamas Pharmaceuticals by 3.5% during the second quarter. Bank of America Corp DE now owns 244,248 shares of the specialty pharmaceutical company’s stock valued at $1,515,000 after buying an additional 8,248 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Adamas Pharmaceuticals by 8.7% during the third quarter. Rhumbline Advisers now owns 37,166 shares of the specialty pharmaceutical company’s stock valued at $190,000 after buying an additional 2,974 shares during the last quarter. Finally, Deltec Asset Management LLC raised its holdings in shares of Adamas Pharmaceuticals by 4.4% during the third quarter. Deltec Asset Management LLC now owns 574,886 shares of the specialty pharmaceutical company’s stock valued at $2,941,000 after buying an additional 24,050 shares during the last quarter. Institutional investors own 51.18% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Featured Story: What is included in the gross domestic product?

Earnings History and Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.